Hyperhomocysteinemia in children treated with antiepileptic drugs is normalized by folic acid supplementation

Epilepsia

Volumn 46, Issue 10, 2005, Pages 1677-1683

  Huemer, Martina ^a   Ausserer, Bernd ^c   Graninger, Gunther ^a   Hubmann, Michael ^a   Huemer, Christian ^b   Schlachter, Kurt ^b   Tscharre, Arthur ^a   Ulmer, Hanno ^d   Simma, Burkhard ^a  

^a Landeskrankenhaus Feldkirch   (Austria)

^b LKH Bregenz ^*  (Austria)

^c Krankenhaus Dornbirn   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Atherosclerosis; Cobalamin; Genetic polymorphisms; Homocysteine metabolism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTICONVULSIVE AGENT; CARBAMAZEPINE; COBALAMIN; CYTOCHROME P450; ETHOSUXIMIDE; FOLIC ACID; GENOMIC DNA; HOMOCYSTEINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; SULTIAME; TOPIRAMATE; VALPROIC ACID; CYANOCOBALAMIN;

ADOLESCENT; ANTICONVULSANT THERAPY; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EPILEPSY; FEMALE; FOLIC ACID BLOOD LEVEL; GENETIC POLYMORPHISM; HUMAN; HYPERHOMOCYSTEINEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; BLOOD; CHEMICALLY INDUCED DISORDER; DIET SUPPLEMENTATION; DRUG COMBINATION; FOLIC ACID DEFICIENCY; TREATMENT OUTCOME;

ANTICONVULSANTS; CHILD; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EPILEPSY; FOLIC ACID; FOLIC ACID DEFICIENCY; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; TREATMENT OUTCOME; VITAMIN B 12;

EID: 27244443366     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.00264.x     Document Type: Article

References (41)

1. Födinger M, Buchmayer H, Sunder-Plassmann G. Molecular genetics of homocysteine metabolism. Miner Electrolyte Metab 1999;25:269-78.
2. Stead LM, Au KP, Jacobs RL, et al. Methylation demand and homocysteine metabolism: effects of dietary provision of creatine and guanidinoacetate. Am J Physiol Endocrinol Metab 2001;281:E1095-100.
3. Födinger M, Hörl WH, Sunder-Plassmann G. Molecular biology of 5,10-methylenetetrahydrofolate reductase. J Nephrol 2000;13:20-33.
4. Finkelstein JD. Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Haemost 2000;26:219-25.
5. van der Put NMJ, Gabreels F, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998;62:1044-51.
6. Prengler M, Sturt N, Krywawych S, et al. Homozygous thermolabile variant of the methylenetetrahydrofolate reductase gene: a potential risk factor for hyperhomocysteinaemia, CVD, and stroke in childhood. Dev Med Child Neurol 2001;43:220-5.
7. Rady PL, Szucs S, Grady J, et al. Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas: a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet 2002;107:162-8.
8. Schneede J, Refsum H, Ueland PM. Biological and environmental determinants of plasma homocysteine. Semin Thromb Haemost 2000;26:263-79.
9. Osganian S, Stampfer MJ, Spiegelman D, et al. Distribution of and factors associated with serum homocysteine levels in children: Child and Adolescent Trial for Cardiovascular Health. JAMA 1999;281:1189-96.
10. De Laet C, Wautrecht JC, Brasseur D, et al. Plasma homocysteine concentration in a Belgian school-age population. Am J Clin Nutr 1999;69:968-72.
11. Vilaseca MA, Moyano D, Ferrer I, et al. Total homocysteine in pediatric patients. Clin Chem 1997;43:690-2.
12. Rauh M, Verwied S, Knerr I, et al. Homocysteine concentrations in a German cohort of 500 individuals: reference ranges and determinants of plasma levels in healthy children and their parents. Amino Acids 2001;20:409-18.
13. Huemer M, Vonblon K, Födinger M, et al. Total homocysteine, folate, cobalamin and their relation to lifestyle, body mass index and genetic polymorphisms in healthy Austrian children and adolescents. Pediatr Res (submitted for publication).
14. van Beynum IM, Smeitink JA, den Heijer M, et al. Hyperhomocysteinemia: a risk factor for ischemic stroke in children. Circulation 1999;99:2070-2.
15. Vilaseca MA, Monros E, Artuch R, et al. Anti-epileptic drug treatment in children: hyperhomocysteinaemia, B-vitamins and the 677C→T mutation of the methylenetetrahydrofolate reductase gene. Eur J Pediatr Neurol 2000;4:269-77.
16. Apeland T, Mansoor MA, Strandjord RE. Antiepileptic drugs as independent predictors of plasma total homocysteine levels. Epilepsy Res 2001;47:27-35.
17. Hustad S, Nedebro BG, Ueland PM, et al. Phenotypic expression of the methylenetetrahydrofolate reductase 677C→T polymorphism and flavin cofactor availability in thyroid dysfunction. Am J Clin Nutr 2004;80:1050-7.
18. Verrotti A, Pascarella R, Trotta D, et al. Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine. Epilepsy Res 2000;41:253-7.
19. Ono H, Sakamoto A, Mizoguchi N, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene contributes to hyperhomocysteinemia in patients taking anticonvulsants. Brain Dev 2002;24:223-6.
20. Schwaninger M, Ringleb P, Winter R, et al. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia 1999;40:345-50.
21. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005;3:292-9.
22. Doshi S, McDowell I, Goodfellow J, et al. Relationship between S-adenosylmethionine, S-adenosylhomocysteine, asymmetric dimethylarginine, and endothelial function in healthy human subjects during experimental hyper- and hypohomocysteinemia. Metabolism 2005;54:351-60.
23. Stühlinger MC, Stanger O. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction. Curr Drug Metab 2005;6:3-14.
24. McCarty MF. Coping with endothelial superoxide: potential complementarity of arginine and high-dose folate. Med Hypotheses 2004;63:709-18.
25. Pena AS, Wiltshire E, Gent R, et al. Folic acid improves endothelial function in children and adolescents with type 1 diabetes. J Pediatr 2004;144:500-4.
26. Ono H, Sakamoto A, Eguchi T, et al. Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants. Metabolism 1997;46:959-62.
27. Marangos PJ, Loftus T, Wiesner J, et al. Adenosinergic modulation of homocysteine-induced seizures in mice. Epilepsia 1990;31:239-46.
28. Ho PI, Ashline D, Dhitavat S, et al. Folate deprivation induces neurodegeneration: roles of oxidative stress and increased homocysteine. Neurobiol Dis 2003;14:32-42.
29. Davis SR, Scheer JB, Quinlivan EP, et al. Dietary vitamin B-6 restriction does not alter rates of homocysteine remethylation or synthesis in healthy young women and men. Am J Clin Nutr 2005;81:648-55.
30. Apeland T, Mansoor MA, Pentieva K, et al. Fasting and postmethionine loading concentrations of homocysteine, vitamin B2, and vitamin B6 in patients on antiepileptic drugs. Clin Chem 2003;49:1005-8.
31. Karabiber H, Sonmezgoz E, Ozerol E, et al. Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid. Brain Dev 2003;25:113-5.
32. James GK, Jones MW, Pudek MR. Homocyst(e)ine levels in patients on phenytoin therapy. Clin Biochem 1997;30:647-9.
33. Kishi T, Fujita N, Eguchi T, et al. Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy. J Neurol Sci 1997;145:109-12.
34. Alonso-Aperte E, Ubeda N, Achon M, et al. Impaired methionine synthesis and hypomethylation in rats exposed to valproate during gestation. Neurology 1999;52:750-6.
35. Yoo JH, Hong SB. A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants. Metabolism 1999;48:1047-51.
36. Geisel J, Hubner U, Bodis M, et al. The role of genetic factors in the development of hyperhomocysteinemia. Clin Chem Lab Med 2003;41:1427-34.
37. Fowler B. Genetic defects of folate and cobalamin metabolism. Eur J Pediatr 1998;157:S60-6.
38. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
39. McKinley MC, McNulty H, McPartlin J, et al. Effect of riboflavin supplementation on plasma homocysteine in elderly people with low riboflavin status. Eur J Clin Nutr 2002;56:850-6.
40. Morrell MJ. Folic acid and epilepsy. Epilepsy Curr 2002;2:31-4.
41. Kim YI. Will mandatory folic acid fortification prevent or promote cancer? Am J Clin Nutr 2004;80:1123-8.